rec-2282 (AR-42)

Status: Unknown

Synonyms:

AR42, OSU-HDAR42, HDAR42,
N-hydroxy-4-(3-methyl-2-phenylbutyrylamino) benzamide

Pharmaceutical Company:

Arno Therapeutics

Legal Status:

℞ - Prescription/Under Clinical Trial

Administered By:

Pill - Oral

Tumor Target:

Meningioma and Schwannoma

Protein Target:

HDACi Inhibitor

NF2 Trials

Recruiting Trial: NCT02282917

Formula:

C₁₈ H₂₀ N₂ O₃

Chemical Name:

(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide

Other Uses

Complete list of other health issues Ohio State University Comprehensive Cancer Center is testing AR-42 on.

NF2 Related Trials

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma. - ClinicalTrials.gov NCT01129193

Phase 1

Sources

• Kim, Bae-Hoon, et al. "NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues." International Journal of Molecular Sciences 25.12 (2024): 6558. https://www.mdpi.com/1422-0067/25/12/6558
• Liva, Sophia G. "Preclinical and clinical investigations of a novel histone deacetylase inhibitor: AR-42 (REC-2282)." Diss. The Ohio State University, 2020.https://etd.ohiolink.edu/acprod/odb_etd/etd/r/1501/10?clear=10&p10_accession_num=osu1586338257085974
• Burns, S. S., Akhmametyeva, E. M., Oblinger, J. L., Bush, M. L., Huang, J., Senner, V., ... & Chang, L. S. (2013). "Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth." Cancer Research, 73(2), 792-803. Source: http://cancerres.aacrjournals.org/content/73/2/792.short | DOI: 10.1158/0008-5472.CAN-12-1888
• Wang, G. H., Jiang, F. Q., Duan, Y. H., Zeng, Z. P., Chen, F., Dai, Y., ... & Zhang, X. K. (2013). "Targeting Truncated Retinoid X Receptor-a by CF31 Induces TNF-a-Dependent Apoptosis." Cancer research, 73(1), 307-318. Source: http://cancerres.aacrjournals.org/content/73/1/307.short
• Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A. "AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.." Neuro-Oncology. Vol. 13, no. 9. (September 2011.): 983-. Source: http://neuro-oncology.oxfordjournals.org/content/13/9/983.short]
• Xu, Weihong, et al. "The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production." Biochemical and biophysical research communications 463.4 (2015): 545-550. Source: https://www.sciencedirect.com/science/article/abs/pii/S0006291X15300048
• CSID: 5293992, http://www.chemspider.com/Chemical-Structure.5293992.html (accessed 20:22, Nov 19, 2017)
• "Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead." MedChemCom (2015) Source: https://pubs.rsc.org/en/content/articlelanding/2015/md/c5md00247h/unauth#!divAbstract DOI: 10.1039/C5MD00247H